IkappaBalpha is required for marginal zone B cell lineage development

Eur J Immunol. 2008 Aug;38(8):2096-105. doi: 10.1002/eji.200838254.

Abstract

Inactivation of members of the nuclear factor-kappaB (NF-kappaB) family results in the decrease or defect of marginal zone B (MZB) cells. It is not known which inhibitors of the NF-kappaB family (IkappaB) are required for MZB cell development. Here, we show that mice with B cell-specific inactivation of the main NF-kappaB inhibitor IkappaBalpha have a marked decrease of MZB cells and their presumed precursors. They exhibited increased mortality rates after blood-borne bacterial infection, indicating the importance of MZB cells for bacterial clearance. In contrast, response to T cell-dependent and -independent antigens resulted only in minor changes in immunoglobulin production. Our data demonstrate the importance of the intact NF-kappaB/IkappaBalpha pathway for proper MZB cell development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • B-Lymphocytes / physiology*
  • Cell Lineage*
  • I-kappa B Proteins / physiology*
  • Mice
  • Mice, Knockout
  • NF-KappaB Inhibitor alpha
  • Receptor, Notch2 / physiology
  • Signal Transduction

Substances

  • I-kappa B Proteins
  • Nfkbia protein, mouse
  • Notch2 protein, mouse
  • Receptor, Notch2
  • NF-KappaB Inhibitor alpha